Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by loss of dopaminergic neurons and localized neuroinflammation occurring in the midbrain several years before the actual onset of symptoms. Neuroinflammation leads to microglia activation and release of a large number of proinflammatory mediators. The kynurenine pathway (KP) of tryptophan catabolism is one of the major regulators of the immune response and is also likely to be implicated in the inflammatory and neurotoxic events in Parkinsonism. Several neuroactive compounds are produced through the KP that can be either a neurotoxic, neuroprotective or immunomodulator. Among these metabolites kynurenic acid (KYNA), produced by astrocytes, is considered as neuroprotective whereas quinolinic acid (QUIN), released by activated microglia, can activate the N-methyl-d-aspartate (NMDA) receptor-signalling pathway, leading to excitotoxicity and amplify the inflammatory response. Previous studies have shown that NMDA antagonists can ease symptoms and exert a neuroprotective effect in PD both in vivo and in vitro. There are to date several lines of evidence linking some of the KP intermediates and the neuropathogenesis of PD. Moreover, it is likely that some of the KP metabolites could be used as prognostic biomarkers and that pharmacological modulators of the KP enzymes could represent a new therapeutic strategy for PD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Quinolinic acid, a QUIN precursor, contributes to neuroinflammation and is implicated in various neurodegenerative diseases.
“previous studies showing that quinolinic acid (QA), a QUIN precursor, contributes to neuroinflammation and is implicated in various neurodegenerative diseases [55,56,57].”
Quinolinic acid released by microglia can activate NMDA receptor signaling, leading to excitotoxicity and increased inflammatory response.
“By contrast, quinolinic acid, released by microglia, can activate the NMDA receptor-signaling pathway, leading to excitotoxicity and increasing the inflammatory response.”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Lim C. K. et al., 2017
The kynurenic pathway is implicated in inflammatory and neurotoxic processes in PD.
“Recently, the kinurenic pathway (KP) has been implicated in the inflammatory and neurotoxic processes in PD.”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Lim C. K. et al., 2017
Cites
1 retracted
Braidy, N., Brew, B. J., Inestrosa, N. C., Chung, R. S., Sachdev, P. S., & Guillemin, G. J. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9557-9 · Cited by 19 · see citing works
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,843 · see citing works
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188 · see citing works
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · see citing works
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757 · see citing works
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,617 · see citing works
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,287 · see citing works
Pesticides and human chronic diseases: Evidences, mechanisms, and perspectives
Mostafalou, S., & Abdollahi, M. R. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.01.025 · Cited by 1,266 · see citing works
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195 · see citing works
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190 · see citing works
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A. K., Simcox, E. M., & Turnbull, D. M. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 961 · see citing works
Perkins, M. N., & Stone, T. W. (1982) · Brain Research · doi:10.1016/0006-8993(82)91048-4 · Cited by 849 · see citing works
Hilmas, C., Pereira, E., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 772 · see citing works
Endogenous kynurenines as targets for drug discovery and development
Stone, T. W., & Darlington, L. G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd870 · Cited by 768 · see citing works
Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism
Fukui, S., Schwarcz, R. M., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03460.x · Cited by 765 · see citing works
Tryptophan and the immune response
Moffett, J., & Namboodiri, M. (2003) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2003.t01-1-01177.x · Cited by 765 · see citing works
Innate immunity: the missing link in neuroprotection and neurodegeneration?
Nguyen, M. D., Julien, J., & Rivest, S. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn752 · Cited by 698 · see citing works
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688 · see citing works
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Bessede, A., Gargaro, M., Pallotta, M. T., Matino, D., Servillo, G., Brunacci, C., Bicciato, S., Mazza, E. M. C., Macchiarulo, A., Vacca, C., et al. (2014) · Nature · doi:10.1038/nature13323 · Cited by 676 · see citing works
Self-citationMetabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 654 · see citing works
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641 · see citing works
DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., & Perdew, G. H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq024 · Cited by 631 · see citing works
Quinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595 · see citing works
Self-citationKynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y.-Q., & Guillemin, G. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 589 · see citing works
Self-citationLill, C., Roehr, J. T., McQueen, M., Kavvoura, F., Bagade, S., Schjeide, B., Schjeide, L. M., Meissner, E., Zauft, U., Allen, N. C., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002548 · Cited by 575 · see citing works
Steiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568 · see citing works
Self-citationKynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru‐Lamoury, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 541 · see citing works
Self-citationBerg, D., Postuma, R. B., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Hardy, J., Lang, A. E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25844 · Cited by 502 · see citing works
Guillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497 · cited 5× · see citing works
“Within the brain, QUIN is only produced by activated microglia and infiltrating macrophages (Guillemin et al., 2003b), but not by neurons or astrocytes (Guillemin et al., 2005c) (Fig.”
BackgroundInfluentialSelf-citationJang, H., Boltz, D., Sturm-Ramirez, K., Shepherd, K., Jiao, Y., Webster, R., & Smeyne, R. J. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0900096106 · Cited by 464 · see citing works
Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K. G., Hansen, A. M., Koni, P. A., Iwashima, M., & Munn, D. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1652 · Cited by 457 · see citing works
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3039 · Cited by 453 · see citing works
Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ávila, M. F., González, J., El-Bachá, R. D. S., Báez-Jurado, E., García‐Segura, L. M., Jurado-Coronel, J. C., Capani, F., Cardona‐Gómez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 453 · see citing works
Parkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 436 · see citing works
Foster, A. C., Vezzani, A., French, E. D., & Schwarcz, R. M. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90050-8 · Cited by 435 · see citing works
Walker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432 · see citing works
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 423 · see citing works
Baltazar, M. T., Dinis‐Oliveira, R. J., Bastos, M. D. L., Tsatsakis, A. M., Duarte, J. A., & Carvalho, F. D. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.01.039 · Cited by 410 · see citing works
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394 · see citing works
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bézard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392 · see citing works
Editorial (Thematic Issue: Mitochondrial Biogenesis: Pharmacological Approaches)
Valero, T. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282035140911142118 · Cited by 369 · see citing works
Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346 · see citing works
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345 · see citing works
Self-citationIndoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus
Guillemin, G., Brew, B., Noonan, C. E., Takikawa, O., & Cullen, K. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00655.x · Cited by 331 · see citing works
Self-citationNiranjan, R. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8483-x · Cited by 331 · see citing works
Characterization of the Kynurenine Pathway in Human Neurons
Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., Takikawa, O., & Brew, B. J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4101-07.2007 · Cited by 325 · see citing works
Self-citationTavares, R. G., Tasca, C. I., Santos, C. E. S., Alves, L. B., Porciúncula, L. O., Emanuelli, T., & Souza, D. O. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00133-4 · Cited by 320 · see citing works
Kynurenine pathway abnormalities in Parkinson's disease
Ogawa, T., Matson, W. R., Beal, M. F., Myers, R. H., Bird, E. D., Milbury, P. E., & Saso, S. (1992) · Neurology · doi:10.1212/wnl.42.9.1702 · Cited by 317 · see citing works
Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., & Bird, E. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb03143.x · Cited by 312 · see citing works
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304 · see citing works
Self-citationInflammation, Glutamate, and Glia in Depression:<i>A Literature Review</i>
McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289 · see citing works
Jang, H., Boltz, D. A., Webster, R. G., & Smeyne, R. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.08.001 · Cited by 289 · see citing works
Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.
Guridi, J., Herrero, M., Luquin, M., Guillén, J., Ruberg, M., Laguna, J., Vila, M., Javoy-Agid, F., Agid, Y., Hirsch, E., et al. (1996) · Brain : a journal of neurology · doi:10.1093/brain/119.5.1717 · Cited by 287 · see citing works
Self-citationCzłonkowska, A., Kohutnicka, M., Kurkowska‐Jastrzębska, I., & Członkowski, A. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0020 · Cited by 279 · see citing works
Quinolinic acid is a potent lipid peroxidant in rat brain homogenates
Rı́os, C., & Santamarı́a, A. (1991) · Neurochemical Research · doi:10.1007/bf00966592 · Cited by 272 · see citing works
Savitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.194 · Cited by 272 · see citing works
Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states
Lévy, R., Hazrati, L., Herrero, M. T., Vila, M., Hassani, O.-K., Mouroux, M., Ruberg, M., Asensi, H., Agid, Y., Féger, J., et al. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00409-5 · Cited by 270 · see citing works
Self-citationZecca, L., Zucca, F. A., Wilms, H., & Sulzer, D. L. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.08.009 · Cited by 265 · see citing works
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257 · see citing works
Self-citationMunn, D. H., & Mellor, A. L. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.11.003 · Cited by 256 · see citing works
Glutamate Receptors as Therapeutic Targets for Parkinsons Disease
Johnson, K. A., Conn, P. J., & Niswender, C. M. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824606 · Cited by 251 · see citing works
Grünblatt, E., Mandel, S. A., Maor, G., & Youdim, M. B. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00397.x · Cited by 246 · see citing works
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244 · see citing works
Barcia, C., Ros, C., Annese, V., Gómez, A., Ros-Bernal, F., Aguado-Yera, D., Martı́nez-Pagán, M., de Pablos, V., Fernández-Villalba, E., & Herrero, M. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.17 · Cited by 242 · see citing works
Self-citationDifferential vulnerability of central neurons of the rat to quinolinic acid
Schwarcz, R., & Köhler, C. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90115-5 · Cited by 239 · see citing works
Organelle-specific initiation of cell death
Galluzzi, L., Bravo-San Pedro, J. M., & Kroemer, G. (2014) · Nature Cell Biology · doi:10.1038/ncb3005 · Cited by 239 · see citing works
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236 · see citing works
Metabolic features of the cell danger response
Naviaux, R. K. (2013) · Mitochondrion · doi:10.1016/j.mito.2013.08.006 · Cited by 235 · see citing works
Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons
Braidy, N., Grant, R., Adams, S., Brew, B., & Guillemin, G. (2009) · Neurotoxicity research · doi:10.1007/s12640-009-9051-z · Cited by 234 · see citing works
Self-citationNeopterin production, tryptophan degradation, and mental depression—What is the link?
Widner, B., Laich, A., Sperner‐Unterweger, B., Ledochowski, M., & Fuchs, D. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00006-5 · Cited by 231 · see citing works
Chapter 36: Astrocytes and Parkinson's disease
Forno, L. S., DeLanney, L. E., Irwin, I., Monte, D. A. D., & Langston, J. W. (1992) · Progress in brain research · doi:10.1016/s0079-6123(08)61770-7 · Cited by 230 · see citing works
Expression of The Kynurenine Pathway Enzymes in Human Microglia and Macrophages
Guillemin, G. J., Smith, D. G., Smythe, G. A., Armati, P. J., & Brew, G. J. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0135-0_12 · Cited by 229 · see citing works
Self-citationBehan, W. M. H., McDonald, M., Darlington, L. G., & Stone, T. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702940 · Cited by 225 · see citing works
NMDA receptors and ligands in the vertebrate CNS
Stone, T. W. (1988) · Progress in Neurobiology · doi:10.1016/0301-0082(88)90027-5 · Cited by 223 · see citing works
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex
Beal, M. F., Matson, W. R., Storey, E., Milbury, P. E., Ryan, E. A., Ogawa, T., & Bird, E. D. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90191-m · Cited by 220 · see citing works
The Physiological Action of Picolinic Acid in the Human Brain
Grant, R., Coggan, S. E., & Smythe, G. A. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2469 · Cited by 219 · see citing works
Perkins, M. N., & Stone, T. W. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21648-2 · Cited by 215 · see citing works
Nigral pathology and parkinsonian signs in elders without Parkinson disease
Buchman, A. S., Shulman, J. M., Nag, S., Leurgans, S. E., Arnold, S. E., Morris, M. C., Schneider, J. A., & Bennett, D. A. (2011) · Annals of Neurology · doi:10.1002/ana.22588 · Cited by 213 · see citing works
Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease
Guillemin, G. J., & Brew, B. J. (2002) · Redox Report · doi:10.1179/135100002125000550 · Cited by 212 · see citing works
Self-citationGoldstein, L. E., Leopold, M. C., Huang, X., Atwood, C., Saunders, A. J., Hartshorn, M. A., Lim, J. T., Faget, K. Y., Muffat, J., Scarpa, R. C., et al. (2000) · Biochemistry · doi:10.1021/bi992997s · Cited by 212 · see citing works
Stone, T. W. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01451-6 · Cited by 211 · see citing works
Barcia, C., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Bautista‐Hernández, V., Poza, M., Fernández-Barreiro, A., Hirsch, É. C., & Herrero, M. T. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206 · see citing works
Self-citationParkinson's disease: Evidence for environmental risk factors
Kieburtz, K. D., & Wunderle, K. B. (2012) · Movement Disorders · doi:10.1002/mds.25150 · Cited by 199 · see citing works
Foster, A. C. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90221-6 · Cited by 194 · see citing works
Dahm, C. C., Moore, K., & Murphy, M. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512203200 · Cited by 194 · see citing works
The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes
Lisi, L., Navarra, P., Feinstein, D., & Russo, C. D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-1 · Cited by 194 · see citing works
de la Cruz, V. P., Carrillo-Mora, P. U., & Santamarı́a, A. (2012) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s8158 · Cited by 193 · see citing works
Pathology associated with sporadic Parkinson’s disease — where does it end?
Braak, H., Müller, C. M., Rüb, U., Ackermann, H., Bratzke, H., de Vos, R. A. I., & Tredici, K. D. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_15 · Cited by 182 · see citing works
Characterisation of the Expression of NMDA Receptors in Human Astrocytes
Lee, M.-C., Ting, K.-K., Adams, S., Brew, B., Chung, R., & Guillemin, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014123 · Cited by 182 · see citing works
Self-citation3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum
Guidetti, P., & Schwarcz, R. M. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00806.x · Cited by 180 · see citing works
Alpha-synuclein spreading in Parkinson’s disease
Recasens, A., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00159 · Cited by 179 · see citing works
Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes
Guillemin, G. J., Croitoru‐Lamoury, J., Dormont, D., Armati, P. J., & Brew, B. J. (2003) · Glia · doi:10.1002/glia.10175 · Cited by 176 · see citing works
Self-citationInflammation in Parkinson’s disease: role of glucocorticoids
Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175 · cited 1× · see citing works
“6) (Herrero et al., 2015).”
Self-citation3‐hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis
LeWitt, P. A., Li, J., Lü, M., Beach, T. G., Adler, C. H., & Guo, L. (2013) · Movement Disorders · doi:10.1002/mds.25555 · Cited by 174 · see citing works
Hyun, D.-H., Lee, M., Hattori, N., Kubo, S.-I., Mizuno, Y., Halliwell, B., & Jenner, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200666200 · Cited by 172 · see citing works
Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.
Widner, B., Leblhuber, F., & Fuchs, D. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200014 · Cited by 171 · see citing works
The sour side of neurodegenerative disorders: the effects of protein glycation
Miranda, H. V., & Outeiro, T. F. (2009) · The Journal of Pathology · doi:10.1002/path.2682 · Cited by 168 · see citing works
The role of inflammation in sporadic and familial Parkinson’s disease
Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 167 · see citing works
Wonodi, I., Stine, O. C., Sathyasaikumar, K. V., Roberts, R. C., Mitchell, B. D., Hong, L. E., Kajii, Y., Thaker, G. K., & Schwarcz, R. M. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.71 · Cited by 166 · see citing works
Ting, K. K., Brew, B. J., & Guillemin, G. J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-36 · Cited by 166 · see citing works
Self-citationKynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions
Barth, M. C., Ahluwalia, N., Anderson, T. J. T., Hardy, G. J., Sinha, S., Alvarez-Cardona, J. A., Pruitt, I. E., Rhee, E. P., Colvin, R. A., & Gerszten, R. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.024042 · Cited by 165 · see citing works
Tas, S. W., Vervoordeldonk, M. J., Hajji, N., Schuitemaker, J. H. N., van der Sluijs, K., May, M. J., Ghosh, S., Kapsenberg, M. L., Tak, P. P., & de Jong, E. C. (2007) · Blood · doi:10.1182/blood-2006-11-056010 · Cited by 162 · see citing works
Oxidative Stress and Microglial Cells in Parkinson's Disease
Peterson, L. J., & Flood, P. M. (2012) · Mediators of Inflammation · doi:10.1155/2012/401264 · Cited by 161 · see citing works
Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line
Eastman, C. L., & Guilarte, T. R. (1989) · Brain Research · doi:10.1016/0006-8993(89)90216-3 · Cited by 161 · see citing works
The quinolinic acid model of Huntington's disease: Locomotor abnormalities
Sanberg, P. R., Calderon, S. F., Giòrdano, M., et al. (1989) · Experimental Neurology · doi:10.1016/0014-4886(89)90170-2 · Cited by 160 · see citing works
LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons
Chu, C. T., Bayır, H., & Kagan, V. E. (2013) · Autophagy · doi:10.4161/auto.27191 · Cited by 159 · see citing works
Steiner, J. H., Bogerts, B., Sarnyai, Z., Walter, M., Gos, T., Bernstein, H., & Myint, A.-M. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.583941 · Cited by 159 · see citing works
NAD<sup>+</sup>metabolism and oxidative stress: the golden nucleotide on a crown of thorns
Massudi, H., Grant, R., Guillemin, G. J., & Braidy, N. (2012) · Redox Report · doi:10.1179/1351000212y.0000000001 · Cited by 158 · see citing works
Self-citationVila, M., Lévy, R., Herrero, M. T., Ruberg, M., Faucheux, B. A., Obeso, J. A., Agid, Y., & Hirsch, É. C. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00765.1997 · Cited by 158 · see citing works
Self-citationThe Kynurenine Pathway in Brain Tumor Pathogenesis
Adams, S., Braidy, N., Bessesde, A., Brew, B. J., Grant, R., Teo, C., & Guillemin, G. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0549 · Cited by 154 · see citing works
Self-citationTufi, R., Gandhi, S., de Castro, I. P., Lehmann, S., Angelova, P. R., Dinsdale, D. D., Deas, E., Plun‐Favreau, H., Nicotera, P., Abramov, A. Y., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2901 · Cited by 153 · see citing works
Quinolinic acid induces oxidative stress in rat brain synaptosomes
Santamarı́a, A., Galván‐Arzate, S., Lisý, V., Ali, S. F., Duhart, H. M., Osorio‐Rico, L., Rı́os, C., & Sut'astný, F. (2001) · Neuroreport · doi:10.1097/00001756-200103260-00049 · Cited by 152 · see citing works
Barcia, C., Ros, C. M., Annese, V., Carrillo-de Sauvage, M. A., Ros-Bernal, F., Gómez, A., Yuste, J. E., Campuzano, C. M., de Pablos, V., Fernandez-Villalba, E., et al. (2012) · Scientific Reports · doi:10.1038/srep00809 · Cited by 150 · see citing works
Self-citationQuinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α
PEMBERTON, L. A., KERR, S. J., SMYTHE, G., & BREW, B. J. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.589 · Cited by 149 · see citing works
Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148 · see citing works
Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology
Adams, S., Teo, C., McDonald, K. L., Zinger, A., Bustamante, S., Lim, C. K., Sundaram, G., Braidy, N., Brew, B. J., & Guillemin, G. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112945 · Cited by 146 · see citing works
Self-citationDynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis
Groves, J. A., Lee, A., Yildirir, G., & Zachara, N. E. (2013) · Cell Stress and Chaperones · doi:10.1007/s12192-013-0426-y · Cited by 143 · see citing works
de Carvalho, L. P., Bochet, P., & Rossier, J. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00091-7 · Cited by 142 · see citing works
Zaitone, S. A., Abo–Elmatty, D. M., & Shaalan, A. A. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.002 · Cited by 141 · see citing works
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141 · see citing works
Self-citationMiranda, A., Boegman, R. J., Beninger, R. J., & Jhamandas, K. H. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00655-0 · Cited by 139 · see citing works
Velozo, H. G., Contreras, F., Prado, C. E., Elgueta, D., Demane, D. F., Bernales, S., & Pacheco, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203121 · Cited by 138 · see citing works
Involvement of quinolinic acid in aids dementia complex
Guillemin, G. J., Kerr, S. J., & Brew, B. J. (2005) · Neurotoxicity Research · doi:10.1007/bf03033781 · Cited by 135 · see citing works
Self-citationGuillemin, G. J., Wang, L. H.-C., & Brew, B. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-16 · Cited by 135 · see citing works
Self-citationTRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson’s disease via CNTF
Nam, J. H., Park, E. S., Won, S.-Y., Lee, Y. A., Kim, K. I., Jeong, J. Y., Baek, J. Y., Cho, E. J., Jin, M., Chung, Y. C., et al. (2015) · Brain · doi:10.1093/brain/awv297 · Cited by 134 · see citing works
Kostrzewa, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4 · Cited by 134 · see citing works
Structural basis of kynurenine 3-monooxygenase inhibition
Amaral, M., Levy, C., Heyes, D. J., Lafite, P., Outeiro, T. F., Giorgini, F., Leys, D., & Scrutton, N. S. (2013) · Nature · doi:10.1038/nature12039 · Cited by 131 · see citing works
Lowe, M. M., Mold, J. E., Kanwar, B., Huang, Y., Louie, A., Pollastri, M. P., Wang, C., Patel, G., Franks, D. G., Schlezinger, J. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087877 · Cited by 130 · see citing works
Santamarı́a, A., & Rı́os, C. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90796-n · Cited by 128 · see citing works
Jauch, D., Urbańska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J., Whetsell, W. O., & Schwarcz, R. M. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)00280-2 · Cited by 127 · see citing works
Graham, W. C., Robertson, R. G., Sambrook, M. A., & Crossman, A. R. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90376-3 · Cited by 126 · see citing works
TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells
Prajapati, P., Sripada, L., Singh, K., Bhatelia, K., Singh, R. K., & Singh, R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.019 · Cited by 123 · see citing works
Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain
Tavares, R. G., Tasca, C. I., dos Santos, C. E. S., Wajner, M., Souza, D. O., & Dutra‐Filho, C. S. (2000) · Neuroreport · doi:10.1097/00001756-200002070-00005 · Cited by 117 · see citing works
Kinases and kinase signaling pathways: Potential therapeutic targets in Parkinson's disease
Wang, G., Pan, J., & Chen, S. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.003 · Cited by 116 · see citing works
Saito, K., Nowak, T. S., Suyama, K., Quearry, B. J., Saito, M., Crowley, J. S., Markey, S. P., & Heyes, M. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb07443.x · Cited by 116 · see citing works
Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat
Danielle G Smith, G. J. G. (2001) · Journal of NeuroVirology · doi:10.1080/135502801300069692 · Cited by 116 · see citing works
Imbalanced Kynurenine Pathway in Schizophrenia
Kegel, M. E., Bhat, M., Skogh, E., Samuelsson, M., Lundberg, K., Dahl, M., Sellgren, C., Schwieler, L., Engberg, G., Schuppe-Koistinen, I., et al. (2014) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s16800 · Cited by 116 · see citing works
Kynurenine metabolism in multiple sclerosis
Hartai, Z., Klivènyi, P., Janáky, T., Penke, B., Dux, L., & Vécsei, L. (2005) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2005.00442.x · Cited by 115 · see citing works
The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine
Eastman, C. L., & Guilarte, T. R. (1990) · Neurochemical Research · doi:10.1007/bf01101711 · Cited by 113 · see citing works
The pharmacological manipulation of glutamate receptors and neuroprotection
Stone, T. W., & Addae, J. I. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01851-4 · Cited by 113 · see citing works
Braidy, N., Grant, R., Adams, S., & Guillemin, G. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07487.x · Cited by 113 · see citing works
Self-citationVazey, E. M., Chen, K. C., Hughes, S. M., & Connor, B. J. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.034 · Cited by 112 · see citing works
Owe‐Young, R., Webster, N. L., Mukhtār, M., Pomerantz, R. J., Smythe, G. A., Walker, D. W., Armati, P. J., Crowe, S. M., & Brew, B. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05241.x · Cited by 112 · see citing works
Sánchez-Guajardo, V., Annibali, A., Jensen, P. H., & Romero‐Ramos, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829768d2 · Cited by 110 · see citing works
Pieper, H. C., Evert, B. O., Kaut, O., Riederer, P. F., Waha, A., & Wüllner, U. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.010 · Cited by 108 · see citing works
In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum
Santamarı́a, A., Jiménez-Capdeville, M. E., Camacho‐Morales, A., Rodrı́guez-Martı́nez, E., Flores, A., & Galván‐Arzate, S. (2001) · Neuroreport · doi:10.1097/00001756-200108280-00020 · Cited by 106 · see citing works
Chiarugi, A., Meli, E., & Moroni, F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00335.x · Cited by 106 · see citing works
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis
Guillemin, G. J., Meininger, V., & Brew, B. J. (2005) · Neurodegenerative Diseases · doi:10.1159/000089622 · Cited by 105 · cited 2× · see citing works
“…et al., 2007), Huntington’s disease (Beal et al., 1990; Jauch et al., 1995; Stone et al., 2012), amyotrophic lateral sclerosis (Chen et al., 2010b; Guillemin et al., 2006), multiple sclerosis (Hartai et al., 2005a; Lim et al., 2010; Rajda et al., 2007), infections (Coutinho et al., 2014;…”
BackgroundSelf-citationSomatic and germline mosaicism in sporadic early-onset Alzheimer's disease
Beck, J. A. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh134 · Cited by 102 · see citing works
Energetic Dysfunction in Quinolinic Acid‐Lesioned Rat Striatum
Bordelon, Y. M., Chesselet, M., Nelson, D. R., et al. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041629.x · Cited by 101 · see citing works
Plátenı́k, J., Stopka, P., Vejražka, M., & Štípek, S. (2001) · Free Radical Research · doi:10.1080/10715760100300391 · Cited by 100 · see citing works
Németh, H., Toldi, J., & Vécsei, L. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_45 · Cited by 99 · see citing works
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases
Nalls, M. A., Brás, J., Hernandez, D. G., Keller, M. F., Majounie, E., Renton, A. E., Saad, M., Jansen, I. E., Guerreiro, R. J., Lubbe, S. J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.028 · Cited by 98 · see citing works
Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease
Hartai, Z., Klivènyi, P., Janáky, T., Penke, B., László, A., & Vécsei, L. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.07.006 · Cited by 98 · see citing works
Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Finsterwald, C., Magistretti, P. J., & Lengacher, S. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710144502 · Cited by 98 · see citing works
Modeling dyskinesia in animal models of Parkinson disease
Morin, N., Jourdain, V. A., & Paolo, T. D. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.01.024 · Cited by 97 · see citing works
The effect of quinolinate on rat brain lipid peroxidation is dependent on iron
Štípek, S., Šťastný, F., Plátenı́k, J., Crkovska, J., & Zima, T. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(97)90002-4 · Cited by 97 · see citing works
The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease
Zinger, A., Barcia, C., Herrero, M. T., & Guillemin, G. J. (2011) · Parkinson s Disease · doi:10.4061/2011/716859 · Cited by 95 · see citing works
Self-citationKynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects
Muller, N., Myint, A.-M., & J. Schwarz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049552 · Cited by 94 · cited 1× · see citing works
“Induction of the KP regulatory enzyme indoleamine 2,3 dioxygenase (IDO-1), KP activation and TRP depletion are involved in the development of immune tolerance related to pregnancy and tenacity of tumours (Munn and Mellor, 2004).”
BackgroundCalon, F., Morissette, M., Ghribi, O., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00237-8 · Cited by 93 · see citing works
Rotenone induces neuronal death by microglial phagocytosis of neurons
Emmrich, J., Hornik, T. C., Neher, J. J., & Brown, G. C. (2013) · FEBS Journal · doi:10.1111/febs.12401 · Cited by 93 · see citing works
Herrero, M. T., Lévy, R., Ruberg, M., Luquín, M. R., Villares, J., López-Guillén, J. L., Faucheux, B. A., Javoy-Agid, F., Guridi, J., Agid, Y., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.219 · Cited by 92 · see citing works
Self-citationGrégoire, L., Rassoulpour, A., GUIDETTI, P., Samadi, P., BEDARD, P., Izzo, E., Schwarcz, R. M., & Paolo, T. D. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.08.007 · Cited by 91 · see citing works
Lu, M., Sun, X., Qiao, C., Liu, Y., Ding, J., & Hu, G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.015 · Cited by 91 · see citing works
Rotenone Directly Induces BV2 Cell Activation via the p38 MAPK Pathway
Gao, F., Chen, D., Hu, Q., & Wang, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072046 · Cited by 91 · see citing works
Anderson, G., & Maes, M. H. J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8554-z · Cited by 90 · see citing works
Antioxidant treatment protects striatal neurons against excitotoxic insults
Nakao, N., Grasbon-Frodl, E. M., Widner, H., & Brundin, P. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00034-6 · Cited by 90 · see citing works
Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol
Khan, M. M., Kempuraj, D., Thangavel, R., & Zaheer, A. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.029 · Cited by 88 · see citing works
Fazio, F., Lionetto, L., Molinaro, G., Bertrand, H., Acher, F., Ngomba, R. T., Notartomaso, S., Curini, M., Rosati, O., Scarselli, P., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.074765 · Cited by 86 · see citing works
Knyihár‐Csillik, E., Mihály, A., Krisztin‐Péva, B., et al. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.04.009 · Cited by 84 · see citing works
der Perren, A. V., Macchi, F., Toelen, J., Carlon, M. S., Maris, M., de Loor, H., Kuypers, D. R. J., Gijsbers, R., den Haute, C. V., Debyser, Z., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.01.014 · Cited by 83 · see citing works
Braidy, N., Grant, R., Brew, B. J., Adams, S., Jayasena, T., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2318 · Cited by 81 · see citing works
Self-citationQuinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites
Jhamandas, K. H., Boegman, R. J., Beninger, R. J., & Bialik, M. (1990) · Brain Research · doi:10.1016/0006-8993(90)90826-w · Cited by 80 · see citing works
Purine metabolism gene deregulation in P arkinson's disease
Garcia‐Esparcia, P., Hernández‐Ortega, K., Ansoleaga, B., et al. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12221 · Cited by 77 · see citing works
Annese, V., Herrero, M. T., Pentima, M. D., Gómez, A., Lombardi, L., Ros, C. M. B., de Pablos, V., Fernández‐Villalba, E., & Stefano, M. E. D. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0718-8 · Cited by 76 · see citing works
Self-citationSundaram, G., Brew, B. J., Jones, S. P., Adams, S., Lim, C. K., & Guillemin, G. J. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0204-5 · Cited by 76 · see citing works
Self-citationSilva‐Adaya, D., de la Cruz, V. P., Villeda‐Hernández, J., Carrillo-Mora, P. U., González-Herrera, I. G., Garcı́a, E., Colín-Barenque, L., Pedraza‐Chaverrí, J., & Santamarı́a, A. (2010) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2010.10.002 · Cited by 75 · see citing works
Ribeiro, C., Grando, V., Dutra, C. S., Wannmacher, C. M., & Wajner, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04199.x · Cited by 73 · see citing works
Pierozan, P., Zamoner, A., Soska, Â. K., Silvestrin, R., Loureiro, S., Heimfarth, L., Souza, T. M., Wajner, M., & Pessoa-Pureur, R. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.009 · Cited by 73 · see citing works
Duty, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00882.x · Cited by 68 · see citing works
Barcia, C., Ros, C. M., Annese, V., Gómez, A. M., Ros‐Bernal, F., Aguado‐Llera, D., Martínez-Pagán, M. E., de Pablos, V., Fernández‐Villalba, E., & Herrero, M. T. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.123 · Cited by 67 · see citing works
Self-citationEvidence for More than One Parkinson's Disease-Associated Variant within the HLA Region
Hill‐Burns, E. M., Factor, S. A., Zabetian, C. P., Thomson, G. J., & Payami, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027109 · Cited by 66 · see citing works
The Kynurenine Pathway in Stem Cell Biology
Jones, S., Guillemin, G., & Brew, B. (2013) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s12626 · Cited by 66 · see citing works
Self-citationChen, Y.-Q., Brew, B. J., & Guillemin, G. J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07159.x · Cited by 65 · see citing works
Self-citationBehan, W. M. H., & Stone, T. W. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704613 · Cited by 65 · see citing works
Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease
Licker, V., Côte, M., Lobrinus, J. A., Rodrigo, N., Kövari, E., Hochstrasser, D. F., Turck, N., Sanchez, J., & Burkhard, P. R. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.02.032 · Cited by 64 · see citing works
Anderson, G., & Maes, M. H. J. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140711091400 · Cited by 64 · see citing works
Kynurenine Pathway and Disease: An Overview
Santamarı́a, A., Cruz, V. L., & Königsberg, M. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707783399229 · Cited by 64 · see citing works
Quinolinic Acid and Active Oxygens
Goda, K., KISHIMOTO, R., Shimizu, S., Hamane, Y., & Ueda, M. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-0381-7_38 · Cited by 64 · see citing works
Goda, K., KISHIMOTO, R., Shimizu, S., Hamane, Y., & Ueda, M. (1996) · PubMed · Cited by 63 · see citing works
Orlando, L. R., Alsdorf, S. A., Penney, J. B., & Young, A. B. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7542 · Cited by 62 · see citing works
Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia
Gellért, L., Fuzik, J., Göblös, A., Sárközi, K., Marosi, M., Kis, Z., Farkas, T., Szatmári, I., Fülöp, F., Vécsei, L., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.069 · Cited by 62 · see citing works
Lee, D., Lee, K., Lee, H. J., et al. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.03.003 · Cited by 61 · see citing works
Shear, D. A., Dong, J., Haik-Creguer, K. L., Bazzett, T. J., Albin, R. L., & Dunbar, G. L. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6767 · Cited by 61 · see citing works
Knyihár‐Csillik, E., Csillik, B., Pákáski, M., Krisztin‐Péva, B., Dobó, E., Okuno, E., & Vécsei, L. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.04.043 · Cited by 61 · see citing works
Luchowski, P., Luchowska, E., Turski, W. A., et al. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00735-8 · Cited by 59 · see citing works
Fernández-Gómez, F.-J., Galindo, M. F., Gómez-Lázaro, M., González-García, C., Ceña, V., Aguirre, N., & Jordán, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.019 · Cited by 59 · see citing works
Understanding the Roles of the Kynurenine Pathway in Multiple Sclerosis Progression
Lim, C. K., Brew, B., Sundaram, G., & Guillemin, G. (2010) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s4294 · Cited by 58 · see citing works
Self-citationSmith, A. J., Smith, R. A., & Stone, T. W. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9034-0 · Cited by 58 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tryptophan metabolism and gut-brain homeostasis
Roth, W., Zadeh, K., Vekariya, R., Ge, Y., & Mohamadzadeh, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062973 · Cited by 519 · see citing works
The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma.
Ramirez, A. I., de Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., López-Cuenca, I., Rojas, P., Triviño, A., & Ramírez, J. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00214 · Cited by 466 · see citing works
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393 · see citing works
Self-citationMicroglia: Agents of the CNS Pro-Inflammatory Response
Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365 · see citing works
Huang, Y., Zhao, M., Chen, X., Zhang, R., Le, A., Hong, M., Zhang, Y., Jia, L., Zang, W., Jiang, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0916 · Cited by 138 · see citing works
“Related underlying mechanisms include NMDAR activation, ROS production [139], lipid peroxidation, and increased levels of nitric oxide synthase [136].”
BackgroundTryptophan metabolism: Mechanism-oriented therapy for neurological and psychiatric disorders
Li, D., Yu, S., Long, Y., Shi, A., Deng, J., Ma, Y., Wen, J., Li, X., Liu, S., Zhang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985378 · Cited by 129 · see citing works
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101 · see citing works
Microglia activation contributes to quinolinic acid-induced neuronal excitotoxicity through TNF-α
Feng, W., Wang, Y., Liu, Z.-Q., Zhang, X., Han, R., Miao, Y.-Z., & Qin, Z.-H. (2017) · Apoptosis · doi:10.1007/s10495-017-1363-5 · Cited by 53 · see citing works
Fongsaran, C., Dineley, K. T., Paessler, S., & Cisneros, I. E. (2024) · Pathogens · doi:10.3390/pathogens13050397 · Cited by 3 · see citing works
- Authors
- Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., & Guillemin, G. J.
- Affiliations
- Macquarie University (AU)
- UNSW Sydney (AU)
- Instituto Murciano de Investigación Biosanitaria (ES)
- Universidade Federal da Bahia (BR)
- The University of Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Corresponding author
- Guillemin, Gilles J.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 155
- Pages
- 76-95
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2322232345
- Cited by
- 159
- References
- 270
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 19 · 2023: 14 · 2022: 17 · 2021: 22 · 2020: 19 · 2019: 22 · 2018: 6 · 2017: 10 · 2016: 3
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Spanish Ministry of Science and Innovation (01293)
- European Community’s Seventh Framework Programme (115009)
- Australian Research Council
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Parkinson's disease, kynurenine pathway, tryptophan catabolism, neuroinflammation, microglial activation, kynurenic acid, quinolinic acid, NMDA receptor, excitotoxicity, dopaminergic neuron loss, neuroprotection, NMDA receptor antagonists, biomarkers, therapeutic target
- MeSH terms
- Animals, Humans, Kynurenine, Parkinson Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review